Debayan De Bakshi

Debayan De Bakshi

Auto-generated profile, based on publicly available information

Debayan De Bakshi

Cellular and Molecular Biology Graduate Program, University of Wisconsin, Madison, WI, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
DBDebayan De Bakshi
Debayan De Bakshi
YCYu-Chia Chen
Yu-Chia Chen
SWShelly M Wuerzberger-Davis
Shelly M Wuerzberger-Davis
MMMin Ma
Min Ma
BWBayley J Waters
Bayley J Waters
SMShigeki Miyamoto
Shigeki Miyamoto
Multiple myeloma (MM), the second most common hematological malignancy, is generally considered incurable because of the development of drug resistance. We previously reported that hyaluronan and proteoglycan link protein 1 (HAPLN1) produced by stromal cells induces activation of NF-κB, a tumor-supportive transcription factor, and promotes drug resistance in MM cells. However, the identity of the cell surface receptor that detects HAPLN1 and thereby engenders pro-tumorigenic signaling in MM cells remains unknown. Here, we performed an unbiased cell surface biotinylation assay and identified chaperonin 60 (CH60) as the direct binding partner of HAPLN1 on MM cells. Cell surface CH60 specifically interacted with TLR4 to evoke HAPLN1-induced NF-κB signaling, transcription of anti-apoptotic genes, and drug resistance in MM cells. Collectively, our findings identify a cell surface CH60-TLR4 complex as a HAPLN1 receptor and a potential molecular target to overcome drug resistance in MM cells.